A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer

被引：0
作者：
Hurvitz, S. A. [1 ]
Galsky, M. D. [2 ]
Shahidi, J. [3 ]
Zhang, G. [4 ]
Raza, S. [3 ]
Necchi, A. [5 ]
机构：
[1] UCLA Med Ctr, Dept Med, Los Angeles, CA USA
[2] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
[3] Daiichi Sankyo Inc, Clin Dev, Basking Ridge, NJ USA
[4] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA
[5] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370TiP
引用
收藏
页数：1
相关论文
共 50 条
[21]   A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. [J].
Siena, Salvatore ;
Di Bartolomeo, Maria ;
Raghav, Kanwal Pratap Singh ;
Masuishi, Toshiki ;
Loupakis, Fotios ;
Kawakami, Hisato ;
Yamaguchi, Kensei ;
Nishina, Tomohiro ;
Fakih, Marwan ;
Elez, Elena ;
Rodriguez, Javier ;
Ciardiello, Fortunato ;
Saxena, Kapil ;
Yamamoto, Eriko ;
Bako, Emarjola ;
Okuda, Yasuyuki ;
Shahidi, Javad ;
Grothey, Axel ;
Yoshino, Takayuki .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[22]   A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator's choice in HER2-low breast cancer. [J].
Modi, Shanu ;
Ohtani, Shoichiro ;
Lee, Caleb C. ;
Wang, Kongming ;
Saxena, Kapil ;
Cameron, David A. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[23]   Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study [J].
Tamura, Kenji ;
Tsurutani, Junji ;
Takahashi, Shunji ;
Iwata, Hiroji ;
Krop, Ian E. ;
Redfern, Charles ;
Sagara, Yasuaki ;
Doi, Toshihiko ;
Park, Haeseong ;
Murthy, Rashmi K. ;
Redman, Rebecca A. ;
Jikoh, Takahiro ;
Lee, Caleb ;
Sugihara, Masahiro ;
Shahidi, Javad ;
Yver, Antoine ;
Modi, Shanu .
LANCET ONCOLOGY, 2019, 20 (06) :816-826
[24]   Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study [J].
Shitara, Kohei ;
Iwata, Hiroji ;
Takahashi, Shunji ;
Tamura, Kenji ;
Park, Haeseong ;
Modi, Shanu ;
Tsurutani, Junji ;
Kadowaki, Shigenon ;
Yamaguchi, Kensei ;
Iwasa, Satoru ;
Saito, Kaku ;
Fujisaki, Yoshihiko ;
Sugihara, Masahiro ;
Shahidi, Javad ;
Doi, Toshihiko .
LANCET ONCOLOGY, 2019, 20 (06) :827-836
[25]   Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01) [J].
Yoshino, Takayuki ;
Di Bartolomeo, Maria ;
Raghav, Kanwal Pratap Singh ;
Masuishi, Toshiki ;
Kawakami, Hisato ;
Yamaguchi, Kensei ;
Nishina, Tomohiro ;
Wainberg, Zev A. ;
Elez, Elena ;
Rodriguez, Javier ;
Fakih, Marwan ;
Ciardiello, Fortunato ;
Saxena, Kapil ;
Kobayashi, Kojiro ;
Bako, Emarjola ;
Okuda, Yasuyuki ;
Meinhardt, Gerold ;
Grothey, Axel ;
Siena, Salvatore .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[26]   Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). [J].
Yoshino, Takayuki ;
Di Bartolomeo, Maria ;
Raghav, Kanwal Pratap Singh ;
Masuishi, Toshiki ;
Loupakis, Fotios ;
Kawakami, Hisato ;
Yamaguchi, Kensei ;
Nishina, Tomohiro ;
Wainberg, Zev A. ;
Elez, Elena ;
Rodriguez, Javier ;
Fakih, Marwan ;
Ciardiello, Fortunato ;
Saxena, Kapil ;
Kobayashi, Kojiro ;
Bako, Emarjola ;
Okuda, Yasuyuki ;
Meinhardt, Gerold ;
Grothey, Axel ;
Siena, Salvatore .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[27]   Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2 [J].
Mutlu, Levent ;
McNamara, Blair ;
Bellone, Stefania ;
Manavella, Diego D. ;
Demirkiran, Cem ;
Greenman, Michelle ;
Verzosa, Miguel Skyler Z. ;
Buza, Natalia ;
Hui, Pei ;
Hartwich, Tobias Max Philipp ;
Harold, Justin ;
Yang-Hartwich, Yang ;
Zipponi, Margherita ;
Altwerger, Gary ;
Ratner, Elena ;
Huang, Gloria S. ;
Clark, Mitchell ;
Andikyan, Vaagn ;
Azodi, Masoud ;
Schwartz, Peter E. ;
Santin, Alessandro D. .
CLINICAL & EXPERIMENTAL METASTASIS, 2024, 41 (05) :765-775
[28]   Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC) [J].
Siena, S. ;
Raghav, K. ;
Masuishi, T. ;
Yamaguchi, K. ;
Nishina, T. ;
Elez, E. ;
Rodriguez, J. ;
Chau, I. ;
Di Bartolomeo, M. ;
Kawakami, H. ;
Suto, F. ;
Kobayashi, K. ;
Koga, M. ;
Inaki, K. ;
Kuwahara, Y. ;
Takehara, I. ;
Grothey, A. ;
Yoshino, T. .
ANNALS OF ONCOLOGY, 2021, 32 :S532-S532
[29]   Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts. [J].
Iwata, Hiroji ;
Tamura, Kenji ;
Doi, Toshihiko ;
Tsurutani, Junji ;
Modi, Shanu ;
Park, Haeseong ;
Krop, Ian E. ;
Sagara, Yasuaki ;
Redfern, Charles H. ;
Murthy, Rashmi Krishna ;
Redman, Rebecca A. ;
Shitara, Kohei ;
Fujisaki, Yoshihiko ;
Sugihara, Masahiro ;
Zhang, Lin ;
Shahidi, Javad ;
Yver, Antoine ;
Takahashi, Shunji .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[30]   Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). [J].
Galsky, Matt D. ;
Del Conte, Gianluca ;
Foti, Silvia ;
Yu, Evan Y. ;
Machiels, Jean-Pascal H. ;
Doger, Bernard ;
Necchi, Andrea ;
De Braud, Filippo G. ;
Hamilton, Erika P. ;
Hennequin, Audrey ;
Van den Mooter, Tom ;
Debruyne, Philip R. ;
Moreno, Irene ;
Arkenau, Hendrik-Tobias ;
Tsuchihashi, Zenta ;
Cheng, Fu-Chih ;
Augustine, Bincy ;
Cheng, Ben ;
Barrios, Daniel ;
Luftner, Diana .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345